Advertisement

Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies

  • Ishak Mansi
    Correspondence
    North Texas Health System, Division of Outcomes and Health Services Research; University of Texas Southwestern Medical Center, 4500S. Lancaster Road #111E, Dallas, TX 75216
    Affiliations
    Division of Outcomes and Health Services Research, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for articles by this author
  • Biff F. Palmer
    Affiliations
    Division of Outcomes and Health Services Research, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for articles by this author

      Abstract:

      Considerable debate exists regarding who might benefit from statins for primary prevention. Statins have wide pleotropic effects, which contribute to their efficacy in lowering cardiovascular disease but may also result in adverse events (AEs). Caveats in identifying AEs in randomized controlled trials (RCTs) include the lack of a standardized definition of statin-associated AEs, the differences in properties of different statins, the selectivity of RCTs in choosing their participants, the presence of high rate of nonadherence/withdrawal from trials and other concerns related to study design and conflict of interest. Caveats in identifying or overestimating AEs in observational studies include failure to identify baseline confounders, ascertainment bias, confounding by indication and healthy user bias. Statin use in observational studies may be a surrogate marker for higher socioeconomic standards, access to health care or use of other preventive services. Integrating evidence from both RCTs and observational studies is of paramount importance for appropriate patient-centered decision.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Robinson J.G.
        • Smith B.
        • Maheshwari N.
        • et al.
        Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
        J Am Coll Cardiol. 2005; 46: 1855-1862
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        New Engl Journal Medicine. 2004; 350: 1495-1504
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        New Engl J Med. 2005; 352: 1425-1435
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of Cardiology/American heart association task force on practice guidelines.
        Circulation. 2014; 129: S1-S45
        • Kolata G.
        Risk calculator for cholesterol appears flawed.
        The New York Times. 2013: A1 (November 18, 2013 ed. New York)
        • Kavousi M.
        • Leening M.J.
        • Nanchen D.
        • et al.
        Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
        JAMA. 2014; 311: 1416-1423
        • Harris D.J.
        • Douglas P.S.
        Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute.
        N Engl J Med. 2000; 343: 475-480
        • Blauwet L.A.
        • Redberg R.F.
        The role of sex-specific results reporting in cardiovascular disease.
        Cardiol Rev. 2007; 15: 275-278
        • Ma Y.
        • Culver A.
        • Rossouw J.
        • et al.
        Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk?.
        Ther Advances Cardiovascular Disease. 2013; 7: 41-44
        • Thavendiranathan P.
        • Bagai A.
        • Brookhart M.A.
        • et al.
        Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.
        Arch Intern Med. 2006; 166: 2307-2313
        • Taylor F.
        • Huffman M.D.
        • Macedo A.F.
        • et al.
        Statins for the primary prevention of cardiovascular disease.
        Cochrane Database Syst Rev. 2013; 1 (CD004816)
      1. Cochrane review stirs controversy over statins in primary prevention. Medscape, Jan 21, 2011 (available at:)
        • Han B.H.
        • Weinberger Y.
        • Sutin D.
        Statinopause.
        J General Internal Medicine. 2014; 29: 1702-1706
        • Finegold J.A.
        • Manisty C.H.
        • Goldacre B.
        • et al.
        What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.
        Eur J Prev Cardiol. 2014; 21: 464-474
        • Gutierrez J.
        • Ramirez G.
        • Rundek T.
        • et al.
        Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis.
        Arch Intern Med. 2012; 172: 909-919
        • Cholesterol Treatment Trialists Collaborators
        Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
        Lancet. 2015; 385: 1397-1405
        • Mansi I.
        • Mortensen E.
        The controversy of a wider statin utilization: why?.
        Expert Opin Drug Saf. 2013; 12: 327-337
        • Martini C.
        • Pallottini V.
        Cholesterol: from feeding to gene regulation.
        Genes Nutr. 2007; 2: 181-193
        • Goedeke L.
        • Fernandez-Hernando C.
        Regulation of cholesterol homeostasis.
        Cell Mol Life Sci. 2012; 69: 915-930
        • Zhou Q.
        • Liao J.K.
        Pleiotropic effects of statins—Basic research clinical perspectives.
        Circ J. 2010; 74: 818-826
        • Chow S.C.
        Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases.
        Arch Immunol Ther Exp (warsz). 2009; 57: 243-251
        • Horton J.D.
        • Goldstein J.L.
        • Brown M.S.
        SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.
        J Clin Invest. 2002; 109: 1125-1131
        • Koh K.K.
        • Sakuma I.
        • Quon M.J.
        Differential metabolic effects of distinct statins.
        Atherosclerosis. 2011; 215: 1-8
        • Matsumoto M.
        • Einhaus D.
        • Gold E.S.
        • et al.
        Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors.
        J Immunol. 2004; 172: 7377-7384
        • De Pinieux G.
        • Chariot P.
        • Ammi-Said M.
        • et al.
        Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio.
        Br J Clin Pharmacol. 1996; 42: 333-337
        • Golomb B.A.
        • Evans M.A.
        Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism.
        Am J Cardiovasc Drugs. 2008; 8: 373-418
        • Swerdlow D.I.
        • Preiss D.
        • Kuchenbaecker K.B.
        • et al.
        HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
        Lancet. 2015; 385: 351-361
        • Thompson P.D.
        • Clarkson P.M.
        • Rosenson R.S.
        An assessment of statin safety by muscle experts.
        Am J Cardiol. 2006; 97: 69C-76C
        • Fernandez G.
        • Spatz E.S.
        • Jablecki C.
        • et al.
        Statin myopathy: a common dilemma not reflected in clinical trials.
        Cleveland Clin J Med. 2011; 78: 393-403
        • Bruckert E.
        • Hayem G.
        • Dejager S.
        • et al.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • Thompson P.D.
        • Clarkson P.
        • Karas R.H.
        Statin-associated myopathy.
        JAMA. 2003; 289: 1681-1690
        • Marie I.
        • Delafenetre H.
        • Massy N.
        • et al.
        Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990–2005 and review of the literature.
        Arthritis Rheum. 2008; 59: 367-372
        • Carmont M.R.
        • Highland A.M.
        • Blundell C.M.
        • et al.
        Simultaneous bilateral Achilles tendon ruptures associated with statin medication despite regular rock climbing exercise.
        Phys Ther Sport. 2009; 10: 150-152
        • Beri A.
        • Dwamena F.C.
        • Dwamena B.A.
        Association between statin therapy and tendon rupture: a case-control study.
        J Cardiovascu Pharmacol. 2009; 53: 401-404
        • Pullatt R.C.
        • Gadarla M.R.
        • Karas R.H.
        • et al.
        Tendon rupture associated with simvastatin/ezetimibe therapy.
        Am J Cardiol. 2007; 100: 152-153
        • Graham D.J.
        • Staffa J.A.
        • Shatin D.
        • et al.
        Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
        JAMA. 2004; 292: 2585-2590
        • Draeger A.
        • Monastyrskaya K.
        • Mohaupt M.
        • et al.
        Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
        J Pathol. 2006; 210: 94-102
        • Phillips P.S.
        • Haas R.H.
        • Bannykh S.
        • et al.
        Statin-associated myopathy with normal creatine kinase levels.
        Ann Intern Med. 2002; 137: 581-585
        • Yang K.C.
        • Chien J.Y.
        • Tseng W.K.
        • et al.
        Statins do not improve short-term survival in an oriental population with sepsis.
        Am J Emerg Med. 2007; 25: 494-501
        • Wagstaff L.R.
        • Mitton M.W.
        • Arvik B.M.
        • et al.
        Statin-associated Memory Loss: Analysis 60 Case Reports Review Literature.
        Pharmacotheraphy. 2003; 23: 871-880
        • Evans M.A.
        • Golomb B.A.
        Statin-associated adverse cognitive effects: survey results from 171 patients.
        Pharmacotherapy. 2009; 29: 800-811
        • Muldoon M.F.
        • Ryan C.M.
        • Sereika S.M.
        • et al.
        Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults.
        Am J Med. 2004; 117: 823-829
        • Mansi I.
        • Frei C.R.
        • Pugh M.J.
        • et al.
        Psychologic disorders and statin use: a propensity score-matched analysis.
        Pharmacotherapy. 2013; 33: 615-626
        • Lilly S.M.
        • Mortensen E.M.
        • Frei C.R.
        • et al.
        Comparison of the risk of psychological and cognitive disorders between persistent and nonpersistent statin users.
        Am J Cardiol. 2014; 114: 1035-1039
        • FDA Drug Saftey Communication
        Important safety label changes to cholesterol-lowering statin drugs. The U S Food and Drug Administration, 2012 (Available at: Accessed July 6, 2015)
        • Hippisley-Cox J.
        • Coupland C.
        Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.
        BMJ. 2010; 340: c2197
        • Mason R.P.
        • Walter M.F.
        • Day C.A.
        • et al.
        Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
        Am J Cardiol. 2005; 96: 11F-23F
        • Hsiang B.
        • Zhu Y.
        • Wang Z.
        • et al.
        A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
        J Biol Chem. 1999; 274: 37161-37168
        • Yamazaki M.
        • Akiyama S.
        • Ni'inuma K.
        • et al.
        Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
        Drug Metab Dispos. 1997; 25: 1123-1129
        • Vgontzas A.N.
        • Kales A.
        • Bixler E.O.
        • et al.
        Effects of lovastatin and pravastatin on sleep efficiency and sleep stages.
        Clin Pharmacol Ther. 1991; 50: 730-737
        • Collins R.
        • Armitage J.
        • Parish S.
        • et al.
        MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
        Lancet. 2003; 361: 2005-2016
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • et al.
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
        Lancet. 2002; 360: 1623-1630
        • Muldoon M.F.
        • Manuck S.B.
        • Mendelsohn A.B.
        • et al.
        Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials.
        BMJ. 2001; 322: 11-15
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
        JAMA. 1998; 279: 1615-1622
      2. Coordinators for the, Allhat Collaborative Research Group The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack, Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
        JAMA. Dec 18 2002; 288: 2998-3007
        • Sever P.S.
        • Dahlof B.
        • Poulter N.R.
        • et al.
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
        Lancet. 2003; 361: 1149-1158
        • Knopp R.H.
        • d'Emden M.
        • Smilde J.G.
        • et al.
        Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
        Diabetes Care. 2006; 29: 1478-1485
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • et al.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • Nakamura H.
        • Arakawa K.
        • Itakura H.
        • et al.
        Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
        Lancet. 2006; 368: 1155-1163
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
        N Engl J Med. 1995; 333: 1301-1307
        • Stewart L.A.
        • Parmar M.K.
        Bias in the analysis and reporting of randomized controlled trials.
        Int J Technol Assess Health Care. 1996; 12: 264-275
        • Kemmler G.
        • Hummer M.
        • Widschwendter C.
        • et al.
        Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
        Arch Gen Psychiatry. 2005; 62: 1305-1312
        • Rothman K.J.
        Six persistent research misconceptions.
        J General Internal Medicine. 2014; 29: 1060-1064
        • Launer L.J.
        • Wind A.W.
        • Deeg D.J.
        Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly.
        Am J Epidemiol. 1994; 139: 803-812
        • Palmer S.C.
        • Craig J.C.
        • Navaneethan S.D.
        • et al.
        Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.
        Ann Intern Med. 2012; 157: 263-275
        • Taylor F.
        • Ward K.
        • Moore T.H.
        • et al.
        Statins for the primary prevention of cardiovascular disease.
        Cochrane Database Syst Rev. 2011; (CD004816)
        • Psaty B.M.
        • Furberg C.D.
        • Ray W.A.
        • et al.
        Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
        JAMA. 2004; 292: 2622-2631
        • Jacobson T.A.
        Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia.
        Mayo Clin Proc. 2008; 83: 687-700
        • Hsia J.
        • MacFadyen J.G.
        • Monyak J.
        • et al.
        Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
        J Am Coll Cardiol. 2011; 57: 1666-1675
        • Buettner C.
        • Davis R.B.
        • Leveille S.G.
        • et al.
        Prevalence of musculoskeletal pain and statin use.
        J General Intern Med. 2008; 23: 1182-1186
        • Buettner C.
        • Rippberger M.J.
        • Smith J.K.
        • et al.
        Statin use and musculoskeletal pain among adults with and without arthritis.
        Am J Med. 2012; 125: 176-182
        • Hoffman R.
        • Lim H.
        Observational study design.
        in: Ambrosius W. Topics in biostatistics. Humana Press, New Jersey, NJ2007: 19-30
        • Hemmila M.R.
        • Birkmeyer N.J.
        • Arbabi S.
        • et al.
        Introduction to propensity scores: a case study on the comparative effectiveness of laparoscopic vs open appendectomy.
        Arch Surg. 2010; 145: 939-945
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613-619
        • Schneeweiss S.
        • Seeger J.D.
        • Maclure M.
        • et al.
        Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.
        Am J Epidemiol. 2001; 154: 854-864
        • Perkins A.J.
        • Kroenke K.
        • Unutzer J.
        • et al.
        Common comorbidity scales were similar in their ability to predict health care costs and mortality.
        J Clin Epidemiol. 2004; 57: 1040-1048
        • Chen D.
        • Restrepo M.I.
        • Fine M.J.
        • et al.
        Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.
        Am J Respir Crit Care Med. 2011; 184: 312-316
        • Boudreau D.M.
        • Yu O.
        • Johnson J.
        Statin use and cancer risk: a comprehensive review.
        Expert Opin Drug Saf. 2010; 9: 603-621
        • Dormuth C.R.
        • Patrick A.R.
        • Shrank W.H.
        • et al.
        Statin adherence and risk of accidents: a cautionary tale.
        Circulation. 2009; 119: 2051-2057
        • Brookhart M.A.
        • Patrick A.R.
        • Dormuth C.
        • et al.
        Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect.
        Am J Epidemiol. 2007; 166: 348-354
        • McWilliams J.M.
        • Zaslavsky A.M.
        • Meara E.
        • et al.
        Impact of medicare coverage on basic clinical services for previously uninsured adults.
        JAMA. 2003; 290: 757-764
        • Friedman E.
        The uninsured. From dilemma to crisis.
        JAMA. 1991; 265: 2491-2495
        • McWilliams J.M.
        Health consequences of uninsurance among adults in the United States: recent evidence and implications.
        Milbank Q. 2009; 87: 443-494
        • Glantz S.
        • Slinker B.
        Primer of applied regression and analysis of variance. 2nd ed. McGraw-Hill, Inc, New York, NY2001
        • Raphael K.G.
        • Cloitre M.
        Does mood-congruence or causal search govern recall bias? A test of life event recall.
        J Clin Epidemiol. 1994; 47: 555-564
        • Patrick A.R.
        • Schneeweiss S.
        • Brookhart M.A.
        • et al.
        The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration.
        Pharmacoepidemiol Drug Saf. 2011; 20: 551-559
        • Campbell M.
        Statistics at square two understanding modern statistical applications in medicine. 1st ed. BMJ, London, England2001
        • Toh S.
        • Hernandez-Diaz S.
        Statins and fracture risk. A systematic review.
        Pharmacoepidemiol Drug Saf. 2007; 16: 627-640
        • Sugiyama T.
        • Tsugawa Y.
        • Tseng C.H.
        • et al.
        Different time trends of caloric and fat intake between statin users and nonusers among US adults: Gluttony in the time of statins?.
        JAMA Intern Med. 2014; 174: 1038-1045
        • Lee D.S.
        • Markwardt S.
        • Goeres L.
        • et al.
        Statins and physical activity in older men: the osteoporotic fractures in men study.
        JAMA internal medicine. Aug 2014; 174: 1263-1270
        • Culver A.L.
        • Ockene I.S.
        • Balasubramanian R.
        • et al.
        Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.
        Arch Intern Med. 2012; 172: 144-152
        • Chen C.W.
        • Chen T.C.
        • Huang K.Y.
        • et al.
        Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country.
        PLoS One. 2013; 8: e71817
        • Currie O.
        • Mangin D.
        • Williman J.
        • et al.
        The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study.
        BMJ Open. 2013; 3: e003475
        • Ridker P.M.
        • Pradhan A.
        • MacFadyen J.G.
        • et al.
        Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
        Lancet. 2012; 380: 565-571
        • Frayling T.M.
        Statins and type 2 diabetes: genetic studies on target.
        Lancet. 2015; 385: 310-312
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Preiss D.
        • Seshasai S.R.
        • Welsh P.
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564